Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Like most drugs, Mounjaro can cause side effects. Hair loss was not a reported side effect of Mounjaro, but it was reported with other GLP-1 agonists. Mounjaro can cause side effects, such as ...

Medicare may cover Mounjaro for type 2 diabetes, but it does not currently cover weight loss medications. If a person is eligible for Mounjaro, coverage may depend on their prescription drug plan ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Lily Allen is sharing details surrounding a recent visit to a treatment center. The singer discussed the visit on the latest episode of her BBC podcast “Miss Me?” with her cohost Miquita ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

“It” being sex, of course. But shortly after beginning a regimen of compounded tirzepatide, the generic version of anti-obesity jabs like Mounjaro, in August, her hankering for hanky-panky vanishe ...

The manufacturer, Eli Lily, offers a Mounjaro savings card. If you qualify, a one-month supply of the medication may cost as low as $25 [11]. The Novo Nordisk Patient Assistance Program (PAP ...